作者
Paul F Brady, Winnie Chua, Frantisek Nehaj, Derek L Connolly, Alya Khashaba, Yanish JV Purmah, Muhammad J Ul‐Qamar, Mark R Thomas, Chetan Varma, Renate B Schnabel, Tanja Zeller, Larissa Fabritz, Paulus F Kirchhof
发表日期
2022/2/15
期刊
Journal of the American Heart Association
卷号
11
期号
4
页码范围
e022833
简介
Background
Natriuretic peptides are routinely quantified to diagnose heart failure (HF). Their concentrations are also elevated in atrial fibrillation (AF). To clarify their value in predicting future cardiovascular events, we measured natriuretic peptides in unselected patients with cardiovascular conditions and related their concentrations to AF and HF status and outcomes.
Methods and Results
Consecutive patients with cardiovascular conditions presenting to a large teaching hospital underwent clinical assessment, 7‐day ECG monitoring, and echocardiography to diagnose AF and HF. NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was centrally quantified. Based on a literature review, four NT‐proBNP groups were defined (<300, 300–999, 1000–1999, and ≥2000 pg/mL). Clinical characteristics and NT‐proBNP concentrations were related to HF hospitalization or cardiovascular death. Follow‐up data were …
引用总数
学术搜索中的文章